BRPI0909628A2 - compostos de azaindol para o tratamento de distúrbios do sistema nervosos central - Google Patents

compostos de azaindol para o tratamento de distúrbios do sistema nervosos central

Info

Publication number: BRPI0909628A2
Authority: BR; Brazil
Prior art keywords: treatment; nervous system; central nervous; system disorders; azaindole compounds
Prior art date: 2008-03-14

Application number

BRPI0909628A

Other languages

English (en)

Inventor

Michael Katzer

Timo Heinrich

Original Assignee

Merck Patent Ges Mit Beschränkter Haftung

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-14

Filing date

2009-02-14

Publication date

2015-09-22

2009-02-14 Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung

2015-09-22 Publication of BRPI0909628A2 publication Critical patent/BRPI0909628A2/pt

Links

125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title 1
208000015114 central nervous system disease Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0909628A 2008-03-14 2009-02-14 compostos de azaindol para o tratamento de distúrbios do sistema nervosos central BRPI0909628A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08004860		2008-03-14
PCT/EP2009/001055 WO2009112139A1 (en)	2008-03-14	2009-02-14	Azaindole compounds for treatment of central nervous system disorders

Publications (1)

Publication Number	Publication Date
BRPI0909628A2 true BRPI0909628A2 (pt)	2015-09-22

Family

ID=40524561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909628A BRPI0909628A2 (pt)	2008-03-14	2009-02-14	compostos de azaindol para o tratamento de distúrbios do sistema nervosos central

Country Status (14)

Country	Link
US (1)	US20110059982A1 (pt)
EP (1)	EP2250170A1 (pt)
JP (1)	JP2011517440A (pt)
KR (1)	KR20100134664A (pt)
CN (1)	CN101970436A (pt)
AR (1)	AR070885A1 (pt)
AU (1)	AU2009225025A1 (pt)
BR (1)	BRPI0909628A2 (pt)
CA (1)	CA2718138A1 (pt)
EA (1)	EA201001425A1 (pt)
IL (1)	IL207914A0 (pt)
MX (1)	MX2010009920A (pt)
WO (1)	WO2009112139A1 (pt)
ZA (1)	ZA201007325B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103420989B (zh) *	2012-05-15	2016-03-23	华中科技大学	苯并二噁烷类衍生物及其应用
WO2015014256A1 (en) *	2013-07-29	2015-02-05	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use thereof
EP3083589B1 (en)	2013-12-20	2019-12-18	Sunshine Lake Pharma Co., Ltd.	Substituted piperazine compounds and methods of use thereof
EP3148846A1 (en) *	2014-06-02	2017-04-05	Johnson Controls Technology Company	Console assembly
US10316025B2 (en)	2015-06-03	2019-06-11	Sunshine Lake Pharma Co., Ltd.	Substituted piperazine compounds and methods of use and use thereof
JP6657974B2 (ja) *	2016-01-12	2020-03-04	トヨタ紡織株式会社	金属樹脂一体成形品及びその製造方法
CN107459510B (zh) *	2016-06-06	2021-06-25	华东师范大学	异恶唑类化合物及其应用
ES2974248T3 (es) *	2017-09-29	2024-06-26	Sunshine Lake Pharma Co Ltd	Compuesto de pirimidin-piperazina sustituido y uso del mismo
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN120025336A (zh) *	2019-12-18	2025-05-23	加利福尼亚大学董事会	Lin28抑制剂和其使用方法
KR102347368B1 (ko) *	2020-11-03	2022-01-07	(주)케이메디켐	신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
WO2024148274A1 (en) *	2023-01-05	2024-07-11	Apellis Pharmaceuticals, Inc.	Complement inhibition
CN120817935A (zh) *	2024-04-15	2025-10-21	复旦大学附属肿瘤医院	一种杂(芳)环取代环状二胺类化合物及其在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3362956A (en) *	1965-08-19	1968-01-09	Sterling Drug Inc	1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4954502A (en) *	1988-06-10	1990-09-04	Bristol-Myers Squibb Company	1-indolyalkyl-4-(substituted-pyridinyl)piperazines
CA2043709C (en) *	1990-06-29	2002-01-22	David W. Smith	Antimigraine alkoxypyrimidine derivatives
HUP0101475A3 (en) *	1998-06-19	2003-01-28	Lundbeck & Co As H	4,5,6 and 7-indole and indoline derivatives, their preparation and use
US6258819B1 (en) *	1999-08-05	2001-07-10	Syntex (U.S.A.) Llc	Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
ATE261959T1 (de) *	1999-12-30	2004-04-15	Lundbeck & Co As H	Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE10112151A1 (de) *	2001-03-14	2002-09-19	Merck Patent Gmbh	Substituierte Benzofuran-2-carbonsäureamide

2009
- 2009-02-14 JP JP2010550053A patent/JP2011517440A/ja active Pending
- 2009-02-14 BR BRPI0909628A patent/BRPI0909628A2/pt not_active IP Right Cessation
- 2009-02-14 EP EP09720748A patent/EP2250170A1/en not_active Withdrawn
- 2009-02-14 US US12/922,567 patent/US20110059982A1/en not_active Abandoned
- 2009-02-14 WO PCT/EP2009/001055 patent/WO2009112139A1/en not_active Ceased
- 2009-02-14 AU AU2009225025A patent/AU2009225025A1/en not_active Abandoned
- 2009-02-14 MX MX2010009920A patent/MX2010009920A/es not_active Application Discontinuation
- 2009-02-14 EA EA201001425A patent/EA201001425A1/ru unknown
- 2009-02-14 KR KR1020107023013A patent/KR20100134664A/ko not_active Withdrawn
- 2009-02-14 CN CN2009801084815A patent/CN101970436A/zh active Pending
- 2009-02-14 CA CA2718138A patent/CA2718138A1/en not_active Abandoned
- 2009-03-13 AR ARP090100900A patent/AR070885A1/es unknown
2010
- 2010-08-31 IL IL207914A patent/IL207914A0/en unknown
- 2010-10-13 ZA ZA2010/07325A patent/ZA201007325B/en unknown

Also Published As

Publication number	Publication date
JP2011517440A (ja)	2011-06-09
EP2250170A1 (en)	2010-11-17
AR070885A1 (es)	2010-05-12
CA2718138A1 (en)	2009-09-17
IL207914A0 (en)	2010-12-30
MX2010009920A (es)	2010-09-30
WO2009112139A1 (en)	2009-09-17
AU2009225025A1 (en)	2009-09-17
CN101970436A (zh)	2011-02-09
US20110059982A1 (en)	2011-03-10
KR20100134664A (ko)	2010-12-23
EA201001425A1 (ru)	2011-06-30
ZA201007325B (en)	2011-06-29

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0909628A2 (pt)	2015-09-22	compostos de azaindol para o tratamento de distúrbios do sistema nervosos central
BRPI0918527A2 (pt)	2015-12-01	compostos para o tratamento de disturbios do cns
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
PL2504005T3 (pl)	2014-03-31	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
CR11019A (es)	2009-10-20	3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
LT2945632T (lt)	2018-05-25	Heterociklo-pakeisti-[1,2,4]triazolo[1,5-c]chinazolin-5-amino junginiai, tinkami centrinės nervų sistemos sutrikimų gydymui arba prevencijai
BR112013021366A2 (pt)	2016-09-13	imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0819241A2 (pt)	2015-05-05	Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
BR112012013260A2 (pt)	2016-03-15	dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
BRPI0816712A2 (pt)	2016-11-08	terapia de intervalo para o tratamento de tinnitus
BRPI0813516A2 (pt)	2014-12-30	Tratamento de distúrbios proliferativos de células b
BRPI1015472A2 (pt)	2015-11-24	métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
BRPI0911577A2 (pt)	2016-01-05	derivados espiro-indol para o tratamento de doenças parasíticas.
BR112014013843A2 (pt)	2017-07-04	uso de dispositivos para o tratamento de doenças neurológicas
PT2838539T (pt)	2017-11-15	Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
IL225438A (en)	2016-11-30	Use of active pharmacological compounds to treat central nervous system deficiencies
IL225668A (en)	2016-12-29	Formulations for the treatment of disorders of the upper respiratory tract
BR112012004836A2 (pt)	2019-09-24	pirazinilpiridinas úteis para o tratamento de doenças proliferativas
EP2400974A4 (en)	2012-12-12	SYNTHETIC DOUBLE BLOCK CO-POLYPEPTIDE HYDROGELS FOR USE IN THE CENTRAL NERVOUS SYSTEM
HUE033690T2 (hu)	2017-12-28	Terápiás szer hangulatzavarokra
BRPI1013245A2 (pt)	2016-04-05	"composto para o tratamento de distúrbios metabólicos"
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0921404A2 (pt)	2016-07-26	sistema para tratamento de superfície de objetos